Resolution of Staphylococcus aureus Biofilm Infection Using Vaccination and Antibiotic Treatment
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Staphylococcus aureus infections, particularly those from methicillin-resistant strains (i.e., MRSA), are reaching epidemic proportions, with no effective vaccine available. The vast number and transient expression of virulence factors in the infectious course of this pathogen have made the discovery of protective antigens particularly difficult. In addition, the divergent planktonic and biofilm modes of growth with their accompanying proteomic changes also demonstrate significant hindrances to vaccine development. In this study, a multicomponent vaccine was evaluated for its ability to clear a staphylococcal biofilm infection. Antigens (glucosaminidase, an ABC transporter lipoprotein, a conserved hypothetical protein, and a conserved lipoprotein) were chosen since they were found in previous studies to have upregulated and sustained expression in a biofilm, both in vitro and in vivo . Antibodies against these antigens were first used in microscopy studies to localize their expression in in vitro biofilms. Each of the four antigens showed heterogeneous production in various locations within the complex biofilm community in the biofilm. Based upon these studies, the four antigens were delivered simultaneously as a quadrivalent vaccine in order to compensate for this varied production. In addition, antibiotic treatment was also administered to clear the remaining nonattached planktonic cells since the vaccine antigens may have been biofilm specific. The results demonstrated that when vaccination was coupled with vancomycin treatment in a biofilm model of chronic osteomyelitis in rabbits, clinical and radiographic signs of infection significantly reduced by 67 and 82%, respectively, compared to infected animals that were either treated with vancomycin or left untreated. In contrast, vaccination alone resulted in a modest, and nonsignificant, decrease in clinical (34% reduction) and radiographic signs (9% reduction) of infection, compared to nonvaccinated animal groups untreated or treated with vancomycin. Lastly, MRSA biofilm infections were significantly cleared in 87.5% of vaccinated and antibiotic-treated animals, while antibiotics or vaccine alone could not significantly clear infection compared to controls (55.6, 22.2, and 33.3% clearance rates, respectively). This approach to vaccine development may lead to the generation of vaccines against other pathogenic biofilm bacteria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms
Donlan, R. M., & Costerton, J. W. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.167-193.2002 · Cited by 6,644
Self-citationKlevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726 · cited 1×
“A recent study has found that nearly 19,000 people per year die from MRSA infections in the United States, a death toll higher than that due to AIDS (16).”
BackgroundWang, R., Braughton, K. R., Kretschmer, D., Bach, T.-H. L., Queck, S. Y., Li, M., Kennedy, A. D., Dorward, D. W., Klebanoff, S. J., Peschel, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1656 · Cited by 1,046 · cited 1×
“aureus cells possess a number of immuno-avoidance strategies, including protein A, leukotoxins, an antiphagocytic capsule, and the recently described phenol soluble modulins and nitric oxide-inducible lactate dehydrogenase system (30, 39) that enable persistence.”
BackgroundVaccine assembly from surface proteins of Staphylococcus aureus
Stranger-Jones, Y. K., Bae, T., & Schneewind, O. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606863103 · Cited by 309
Richardson, A. R., Libby, S. J., & Fang, F. C. (2008) · Science · doi:10.1126/science.1155207 · Cited by 296 · cited 1×
“aureus cells possess a number of immuno-avoidance strategies, including protein A, leukotoxins, an antiphagocytic capsule, and the recently described phenol soluble modulins and nitric oxide-inducible lactate dehydrogenase system (30, 39) that enable persistence.”
BackgroundKuklin, N. A., Clark, D. J., Secore, S., Cook, J., Cope, L. D., McNeely, T., Noble, L., Brown, M. J., Zorman, J. K., Wang, X. M., et al. (2006) · Infection and Immunity · doi:10.1128/iai.74.4.2215-2223.2006 · Cited by 264 · cited 2×
“A number of vaccines have been evaluated for their protective efficacy against staphylococcal infections, in particular against a primary planktonic bacteremia, pneumonia, septic arthritis, and intraperitoneal staphylococcal infection (6, 15, 18, 24, 25, 34, 37).”
Background
Cited by
Targeting microbial biofilms: current and prospective therapeutic strategies
Koo, H., Allan, R. N., Howlin, R. P., Stoodley, P., & Hall-Stoodley, L. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.99 · Cited by 1,800
Lebeaux, D., Ghigo, J.-M., & Beloin, C. (2014) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00013-14 · Cited by 1,318
The role of bacterial biofilms in chronic infections
Bjarnsholt, T. (2013) · APMIS · doi:10.1111/apm.12099 · Cited by 1,080
Arciola, C. R., Campoccia, D., Speziale, P., Montanaro, L., & Costerton, J. W. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.031 · Cited by 1,047
Self-citationStaphylococcus aureus biofilms: Properties, regulation, and roles in human disease
Archer, N. K., Mazaitis, M. J., Costerton, J. W., Leid, J. G., Powers, M. E., & Shirtliff, M. E. (2011) · Virulence · doi:10.4161/viru.2.5.17724 · Cited by 1,018
Self-citation
Metadata
- Authors
- Brady, R. A., O'May, G. A., Leid, J. G., Prior, M. L., Costerton, J. W., & Shirtliff, M. E.
- Venue
- Infection and Immunity
- Publisher
- American Society for Microbiology
- Published
- 2011-04
- Volume
- 79
- Issue
- 4
- Pages
- 1797-1803
- ISSN
- 0019-9567 (ISSN-L)
- 1098-5522
- OpenAlex
- W2165512947
- Cited by
- 143
- References
- 6
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.